Previous 10 | Next 10 |
Summary Except for "Jobs", economic data dictates the economy is in a state of "contraction" while Inflation remains "sticky". The recent rally is focused on the notion of a soft landing and the impact the China re-opening will have on the global scene. There is nothing in this econ...
Summary The CGM market is expected to grow due to the rising prevalence of diabetes and the adoption of CGM technology among insulin-intensive patients. DexCom's 4Q22 sales were $815 million, with positive volume growth across the board and strong gross and operating margins. I expe...
Many stocks are still shifting between sharp highs and lows these days, but wonderful businesses continue to impress investors even in the current environment. Looking beyond share price, you don't have to search hard to find compelling businesses with abundant growth opportunities that boast str...
The healthcare industry may not be the most exciting place to invest at first glance. However, it's often these very companies that have businesses primed to weather market and economic storms because of the non-cyclicality of their products and services. If you're looking for two superior he...
U.S. Centers for Medicare & Medicaid Services has approved coverage for Dexcom G7, the most accurate, 1 easy-to-use CGM system that helps people with diabetes gain greater control of their health. Introduced to the world yesterday in a Super Bowl ad , Dexcom G7 eliminates rout...
Super Bowl LVII is on Sunday. If you aren't that interested in watching the game itself, perhaps you'll tune in for the halftime show featuring Rihanna...or the ads, which are the most expensive to air the entire year. If you're a regular NFL viewer, you'll know that healthcare companies aren...
DexCom is up 10% in late Friday morning trading as the continuous glucose monitoring company benefits from quarterly results that beat on the bottom line . In its Q4 2022 results conference call after the closing bell Thursday, the company said it has already ramped up production ...
DexCom, Inc. (DXCM) Q4 2022 Earnings Conference Call February 9, 2023 16:30 ET Company Participants Sean Christensen - Vice President of Finance & Investor Relations Jereme Sylvain - Executive Vice President & Chief Financial Officer Kevin Sayer - Executive Cha...
Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q4 2022 Earnings Call Feb 09, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: DexCom (DXCM) Q4 2022 Earnings Call Transcript
DexCom ( NASDAQ: DXCM ) is up 4% in after-hours trading after the continuous glucose monitor company saw its Q4 2022 financial results beat on the bottom line . Non-GAAP net income $136.3M ($0.34 per diluted share) for the quarter compared to a net loss of $2.4M ($0.01) ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 10:00:00 ET Growth-oriented investors have experienced a bit of a roller-coaster ride over the past few years. Many companies in the "growth stock" category were struggling just two years ago, but in the bull market we are now experiencing, they're delivering very different resul...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...